^
    Back
    Association details:
    Biomarker:HER-2 overexpression
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Enhertu (fam-trastuzumab deruxtecan-nxki) (Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/09/2021
    Excerpt:
    Esophageal and esophageal junction cancer Gastric cancer: Preferred regimens...Fam-trastuzumab deruxtecan-nxki for her2 overexpression positive adenocarcinoma
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

    Excerpt:
    ...- Advanced breast cancer with HER2 overexpression that is refractory to or intolerable with standard treatment, or for which...
    Trial ID:
    DS8201-A-J101
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase 2 Study of T-DXd in the Neoadjuvant Treatment for Patients With HER2 Positive Gastric and GEJ Adenocarcinoma

    Excerpt:
    ...Has HER2 overexpression (IHC3+, or IHC2+ and ISH positive [FISH or DISH])....
    Trial ID:
    EPOC2003